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INTRODUCTION
Juvenile Idiopathic Arthritis (JIA) describes a clinically
heterogeneous group of arthritides of unknown etiology
that begins before the 16th birthday and persists for at
least 6 weeks.1 JIA is the most common chronic
rheumatic disease in children and is an important cause
of short and long-term disability.2 JIA encompasses
several disease categories; each has different modes of
presentation, clinical signs, and symptoms, and in some
cases, genetic background.3 Almost all children with
arthritis report chronic or recurrent pain with restricted
physical activity and limited use of upper limbs or hands.
There is a scarcity of data and established registries
reported prevalence varying between 16 and 150 per
100,000.1 JIA has the potential to cause long-term
disability and leave a lasting impact on the quality of life
of affected children.
Different classification systems have been developed so
far and are still being evolved. Most widely accepted
classification worldwide is developed by the International
League Against Rheumatism (ILAR). According to ILAR
classification, JIA has been divided into eight different
subtypes.4 Nevertheless, despite a dramatic advance in
the understanding of JIA subtypes, pathobiology and
management, much remains to be done.5
New advances in pharmacologic treatments have shown
robust results. Even though none of the available drugs
has a curative potential, prognosis of JIA has greatly
improved as a result over the years.6 Early interventions
with disease-modifying anti-rheumatic drugs may help
minimize joint damage7 and increase remission rates.8
However, use of such drugs can be complex, particularly
in terms of appropriate dosing and monitoring for
possible adverse effects in children. Moreover, the long-
term effects of these medications in children are still
unexplained.9
International research networks of paediatric rheuma-
tology have contributed to fostering the conduct of
controlled clinical trials and also the development of
validated outcome measures. JIA has been extensively
studied in the Western population, but there is a dearth
of local data about the disease profile. This study was
consequently undertaken to determining the clinical and
biochemical characteristics of JIA in children and their
outcome over a period of 4 years.
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ABSTRACT
Objective: To determine the clinical and biochemical characteristics of children with Juvenile Idiopathic Arthritis (JIA) at a
tertiary care centre in Karachi, Pakistan.
Study Design: A descriptive study.
Place and Duration of Study: Paediatric Rheumatology Clinic of The Aga Khan University Hospital (AKUH), Karachi,
from January 2008 to December 2011.
Methodology: Clinical and laboratory profile and outcome of children less than 15 years of age attending the Paediatric
Rheumatology Clinic of the Aga Khan University, Karachi with the diagnosis of Juvenile Idiopathic Arthritis according to
International League against Rheumatism were studied. These children were classified into different types of JIA; their
clinical and laboratory characteristics, response to therapy and outcome was evaluated.
Results: Sixty eight patients satisfying the criteria of International League against Rheumatism (ILAR) for Juvenile
Idiopathic Arthritis were enrolled during the study period of four consecutive years, their age ranged from 9 months to 15
years. Mean age at onset was 6.45 ± 4.03 years while mean age at diagnosis was 7.60 ± 3.93 years. Polyarticular was
the most predominant subtype with 37 (54%) patients, out of these, 9 (24%) were rheumatoid factor positive. An almost
equal gender predisposition was observed. Fever and arthritis were the most common presenting symptoms, with only 2
patients presenting with uveitis.
Conclusion: The clinico-biochemical characteristics of JIA at the study centre showed a pattern distinct with early onset
of disease, high frequency of polyarticular type and a higher rheumatoid factor (QRA) and ANA positivity in girls.
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METHODOLOGY
This cohort descriptive study was carried out at The Aga
Khan University Hospital (AKUH), Karachi, Pakistan. It
included patients presenting to the specialist paediatric
rheumatology clinic, from January 2008 to December 2011.
A retrospective review of file was done and information
was collected via a structured proforma prepared for the
study. Data pertaining to JIA subtype, gender, age at
onset of symptoms and age at diagnosis, joint
involvement, and laboratory parameters included
inflammatory markers e.g. leucocytes, platelets,
Erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP), presence or absence of rheumatoid
factor (QRA) and Anti-nuclear antibody (ANA) positivity
were collected. In addition, different therapeutic regimen
offered and their response was also observed.
Detailed history from patients and their parents/
guardians were taken; a complete clinical examination
including musculoskeletal examination was performed
by the treating physician. Patients who satisfied the
ILAR criteria of JIA were subsequently included in the
study. Children having other possible causes of arthritis
were excluded. Patients were then further classified
according to ILAR classification of the disease into
polyarticular rheumatoid factor positive or negative,
oligoarticular persistent and extended, systemic-onset,
psoriatic, enthesitis-related and undifferentiated JIA sub-
types depending upon number of joints involved and
other systemic features were included in the study.
Data was entered, validated and analyzed using
Statistical Package for Social Sciences (SPSS) version
19.0. Mean and standard deviation were expressed for
numerical variables while frequencies and percentages
were expressed for categorical variables.
As per Ethical Review Committee (ERC) guidelines at
The Aga Khan University Hospital (AKUH), the study
protocol was granted exemption (1935-Ped-ERC-11).
RESULTS
A total of 68 patients with the clinical diagnosis of JIA
were included. The gender distribution was almost equal
33:35 (M: F 0.9:1) except in the systemic onset where
the female ratio was almost double than the male (M: F
1:2). The minimum age of presentation was 9 months
while the maximum age was 15 years. The mean age at
onset of disease was 6.45 ± 4.03 years. The mean age
at diagnosis was 7.60 ± 3.93 years; with systemic onset
JIA being the youngest 4.43 ± 2.55 followed by poly-
articular subtype 7.80 ± 3.82 while oligoarticular subtype
were 8.59 ± 4.08 respectively. There were three peaks of
age of presentation at 3, 6 and 12 years   (Figure 1).
Polyarticular subtype was the predominant type (n=37,
54% cases) in this study, out of which 9 (24%) were
QRA positive with male to female ratio of 3:6.
Oligoarticular was the second common subtype (n=19,
28%). Among them, 7 were extended subtype, all males
and QRA positive. Nine (13%) patients were of systemic
onset subtype. There were 2 cases of enthesitis-related
arthritis and one with psoriatic arthritis.
Knee was the most frequently involved joints in all three
types of JIA followed by ankle with a collective frequency
of almost 80%. Wrist, elbow, metacarpo-phalangeal,
proximal and distal inter-phalangeal joints are the other
joints involved in decreasing order of frequency mostly in
polyarticular type.
Various laboratory parameters in patients with JIA are
shown in Table 1. Most of the biochemical markers were
elevated in systemic onset and polyarticular type JIA.
Complete blood count showed that overall 39 (57%)
patients were anemic (hemoglobin < 10 g/dl) at
presentation, among them the majority was systemic
onset and polyarticular subtypes with the frequency of 8
(89%) and 22 (60%) respectively. White cell counts were
raised (> 11,000/mm3) in a total of 23 (34%) patients;
67% of these were of systemic onset type. Twenty nine
(43%) had thrombocytosis (platelet count > 45000/
cumm) with the preponderance of systemic onset type 8
out of 9 (89%). Other acute phase reactants, including
ESR and CRP, were also raised in most of the patients
with the frequency of 52 (77%) and 50 (74%)
respectively. It was observed that almost all patients
with systemic onset type had high ESR and CRP
(Table I). Overall positivity of rheumatoid factor was 22
(32%). Among them, majority 42% of patients were of
oligoarticular types. ANA was positive in 11 (16%)
patients with significant female predominance (M:F =
2:9); majority of them (6) were also of oligoarticular type
while 4 of polyarticular and only one patient with
systemic onset type had ANA positive.
Outcome was analyzed as response to therapy at the
time of last follow-up. Mean follow-up was 27.5 months
with the duration ranged from 4 to 45 months (Table II).
The Carol Wallace criterion were applied based on
Delphi questionnaire which defined 3 stages of disease:
inactive disease, clinical remission on medication, and
clinical remission off medication.17
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Figure 1: JIA -Age at presentation.
The overall response rate to therapy was 86% (n=44)
out of 51 patients who continued to follow in the clinic.
Among those, 32 (62.5%) had clinical remission off
medication and 12 (23.5%) had clinical remission on
medication while 4 (8%) still had the active disease in
their last follow-up. Best response was seen in
oligoarticular persistent subtype while worse in
polyarticular subtypes who are QRA positive. Seventeen
(25%) were lost to follow-up due to accessibility, as they
were from remote areas of the country. Three patients
died, one with systemic onset type who subsequently
develop macrophage activation syndrome. Two cases of
polyarticular type died because of systemic tuberculosis
and acute leukemia respectively. Two patients of
systemic onset subtype presented with pericardial
effusion, one of them require drainage while 2 patients
of oligoarticular subtype develop uveitis both of them
were ANA positive but none of them experienced visual
loss. None of our patient developed amyloidosis.
DISCUSSION
Juvenile idiopathic arthritis is not an uncommon disease
in children. Various characteristic of the disease have
been widely studied in the developed countries; only few
studies have been published from developing countries
especially South Asian nations. So far, only one study is
available from Pakistan which observes the pattern of
juvenile idiopathic arthritis.10
Gender distribution in this study showed almost equal
male to female ratio. (M: F =0.9:1) except in systemic
onset JIA, where there were more females than males,
in line with local data available from Pakistan;10 it also
corresponds well with the studies done in European
countries like UK and Germany.11,12 However, data from
neighbouring countries like India, Bangladesh and
Turkey report a significant male preponderance.13-15
The mean age at onset of the disease was 6.45 ± 4.03
years and the mean age of diagnosis was 7.60 ± 3.93
years. The age at onset in these children was
comparatively younger than in the other studies which
was 6.9 years in Turkish children,15 10.7 years as
described by Nighat et al.10 and 11.8 years in African
children,16 but comparable with an Indian study.13
Among different subtypes, systemic onset JIA presents
quite early at 4.3 ± 2.57, while oligoarticular presented at
7.00 ± 4.66 years.
The time elapsed from the onset of symptoms to the
actual diagnosis was 1.15 years. This delay in diagnosis
might be due to fact that such patients initially are dealt
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Table I: Laboratory parameters in JIA.
JIA sub-type Systemic onset (n=9) Poly articular (n=37) Oligoarticular (n=19) Psoriatic/enthesitiis Overall
(%)(overall%) (%)(overall%) (%)(overall%) related arthritis (n=3) n = 68 (%)
(%) (overall%)
HB < 10 g/dl 8 (89) 22 (60) 9 (47) - 39 (57)
WBC counts > 11,000/cu mm 6 (67) 12 (32) 5 (26) - 23 (34)
Platelet (> 450,000/cu mm) 8 (89) 19 (51) 3 (16) - 29 (43)
ESR (> 20 mm/hr) 8 (89) 29 (78) 15 (79) - 52 (77)
CRP (> 1) 9 (100) 27 (73) 14 (74) - 50 (74)
QRA +ve 2 (22) 12 (32) 8 (42) - 22 (32)
ANA +ve 1 (11) 4 (11) 6 (32) - 11 (16)
Table II: Outcome of different types of JIA.
Systemic onset (n=9) Polyarticular (n=37) Oligoarticular (n=19) Psoriatic / enthesitis Overall (%)
related arthritis (n=3)
Remission off medication 5 14 10 3 32 (47.1%)
Remission on medication 1 7 4 - 12 (17.6%)
Active disease - 3 1 - 4 (5.8 %)
Expired 1 2 - - 3 (4.4 %)
Lost to follow-up 2 11 4 - 17 (25%)
Table III: Comparative clinical and biochemical characteristics of JIA in various studies.
AKU Lahore10 India13 Bangladesh14 Turkey15 United Kingdom11 Germany12
Number 68 91 74 132 196 572 172
Female: Male 35:33 49:42 26:48 34:89 94:102 384:188 118:54
Mean age of onset 6.45 10.76 6.4 7.5 6.9 - -
Systemic onset (%) 13 4.4 14.9 6.8 15.3 14.7 17.4
Polyarticular (%) 54 44 37.8 47 37.2 24.7 28.7
Oligoarticular (%) 28 51.6 47.3 34.1 34.1 43.7 27.3
QRA (%) 33 48.4 2.7 5.3 8.1 5.2 2.9
ANA (%) 15 - 1 - 14.2 33 41.2
Psoriatic arthritis (%) 1.5 - - 1.5 1 7.5 4.6
Uveitis (n) 2 - 1 12 4 114 21
by family physicians and referred to the general
paediatricians after a couple of months of exhaustive
treatment when symptoms do not settle. In addition,
numbers of patients of oligoarticular JIA were initially
treated as septic arthritis or rheumatic fever. Also, few of
these patients were initially managed by the orthopaedic
surgeons and had joint aspirate and synovial biopsy
done before referral to rheumatology services.
In terms of disease characteristics, 37 (54%) were
polyarticular with oligoarticular being the second
commonest 19 (28%). Systemic onset JIA being the
least frequent 9 (13%) subtype. The same sequence
was observed in Turkey, Bangladesh and Germany in
contrast with the studies from Lahore, India and UK
where oligoarticular was most frequent subtype. One
limitation of the study was the large selection bias as
there was a high frequency of polyarticular subtype in
these children. That might be due to the fact that these
children perhaps had an extended oligoarticular phase
due to delay in referral to the paediatric rheumatologist.
Knee and ankle were the most frequently affected joints
accounting for an 80% of the cases in both poly and
oligoarticular subtypes. Other joints that were involved,
in order of frequency were the wrist, elbow, shoulder,
metacarpo-phalangeal, inter-phalangeal and hip joints.
This is comparable to data reported in other studies by
Seth et al., Aggarval et al. and Singh et al.13,18,22
Ninety percent of cases of uveitis occur within 4 years of
diagnosis of JIA.23 The incidence of uveitis is quite high
among children of developed countries like UK and
Germany but considerably low among children of south
Asian countries. Similar trend was seen in this study as
well, where only 2 patients had uveitis; both had
oligoarticular subtype with ANA positivity. One possible
reason for this could be the delay in diagnosis of the
development of uveitis in our set up, where many
general practitioners would by-pass it as a simple
conjunctivitis. We recommend regular screening by an
ophthalmologist. Newly diagnosed patients are ideally
screened within 6 weeks of diagnosis.24
The QRA factor positivity generally predicts the
unfavourable outcome and poor response to therapy.
QRA factor among these children was undoubtedly
higher (32%) than that reported from neighbouring and
other parts of the world (Table III).11-15 These findings
were reflected in another study available from Pakistan
48.4%  which indicates that one-third to half patients of
JIA from Pakistan are QRA positive.10 Long-term follow-
up of these patients will estimate the significance of
QRA positivity in our population as these patients
responded surprisingly well to treatment despite positive
QRA factor. ANA prevalence in current study was 16%
which is comparable with the Turkish population but
quite low in contrast to other European studies.11,12,15
NSAIDs were used as the most commonly prescribed
drugs in our patients. Naproxen and ibuprofen were
preferred in majority of the patients due to easy
availability and better tolerance; indomethacin was also
used in a few patients as the first line agent.
Methotrexate was the second preferred agent used
mostly in polyarticular subtype and in a few cases of
oligoarticular extended and systemic onset subtypes,
who showed poor or no response to NSAIDs in 4 - 6
weeks time. Corticosteroids were used in all patients of
systemic onset type while in few patients with
polyarticular and extended oligoarticular subtypes,
where inadequate response to NSAIDs and metho-
trexate were observed. Thomas et al. reported a
standardized mortality ratio for females of 5.1 and males
of 3.4.25 In 2010, this is reported to have reduced to 0.57
(males and females combined).26 Combination therapy
of two or more drugs such as, NSAIDs with
methotrexate, NSAIDs with steroids or NSAIDs with
methotrexate and steroids was required in selected
cases of polyarticular QRA positive and extended
oligoarticular subtypes. Sulphasalazine and hydro-
xychloroquine were used mostly in patients with
polyarticular disease with QRA positive as an adjunctive
therapy with NSAIDs and methotrexate. We did not
observe any major side effects that would require
discontinuation of the medicines. Most patients expe-
rienced mild to moderate gastrointestinal discomfort
with nausea and vomiting mainly with methotrexate and
sulphasalazine. These symptoms were successfully
managed with gastro-protective agents in the form of
antacids and proton pump inhibitors. Folic acid
supplements were used in all patients requiring
methotrexate.
The high rate of loss to follow-up could also be attributed
to the fact that most of our patients hailed from a lower
socioeconomic background and the cost of transport
from their areas to the main city was quite high.
Introduction of the biologic agents in the management of
JIA opens a new era in the prognosis and long-term
outcome of the disease and the better future
prospects.19-21 Unfortunately, we did not use biological
agents in any of our patient because of the various
reasons. Only few studies are available regarding the
efficacy and safety of these agents in paediatric age
group, therapy is quite expensive and not widely
available in Pakistan. Few patients who remain have
active disease despite of aggressive management are
the best candidates for biologic therapy in this study.
CONCLUSION
It can be safely concluded from our study that the clinical
and biomedical characteristics of Pakistani children are
somewhat different from those of European and other
neighbouring countries. We feel that there is still
deficiency in understanding of the diagnosis and optimal
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care of JIA. We recommend early referral and multi-
disciplinary approach for these patients to ensure
prompt treatment, thereby improving their long term
follow-up and outcome. There is still a need of further
research on JIA from the country to enhance our
understanding about the clinical and biological
characteristics of JIA and also measure the long term
outcome with reference to impact on growth and health
of our children.
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